What's new?
04/04/2018

• Sofinnova Crossover Fund 1 is the largest healthcare crossover fund focused on Europe.
• With this new fund, Sofinnova Partners actively pursues the strategy to broaden its Life Sciences platform to invest across the value chain, from seed stage to late-stage companies.
• Bpifrance* and CNP Assurances acted as sponsors for the fund.

Paris, France – April 4th, 2018 — Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced today the launch of Sofinnova Crossover I with €275 million ($340 million), above the original first close target of €250 million. With this new fund, Sofinnova Partners goes one step further in the execution of its growth plan, aimed at expanding its coverage across the Life Sciences space with dedicated sector teams.

Pursuing a strategy Sofinnova Partners has successfully applied for decades with its early-stage focused Capital Funds, Sofinnova Crossover I will invest in the biopharmaceutical and medical device sectors. The fund will focus primarily on therapeutic and game-changing companies driven by experienced management. As a lead or cornerstone investor, the fund will seek to invest in about 15 late stage private and public companies. About 80% of the investments will be made in European companies, with the remaining 20% outside of Europe primarily in North America. A dedicated, highly experienced team of four partners will invest Sofinnova Crossover I, leveraging on Sofinnova Partners’ wider experience, track record and organizational support. This new fund attracted premier international investors, predominantly sovereign funds, insurance companies, corporations and family offices. Commitments came from Europe, including France, Italy, Denmark, Ireland, and Switzerland but also from Asian investors in China and Singapore. In addition to Bpifrance* and CNP Assurances, investors include a major Chinese biopharmaceutical company, the Danish State Investment fund, and family offices like Fidim or KCK representing leading industrial families in Europe and Asia.

Antoine Papiernik, Chairman of Sofinnova Partners, said, “With the launch of this new crossover activity, Sofinnova builds upon its unique early stage track record. Many of the companies we initially funded have become over the years large, billion-euro companies, and we have gained invaluable experience in helping them to the next level. This fund will complete our investment platform across the life-sciences value-chain, allowing us to fund companies from the seed stage to the late-stage.”

Jacques Theurillat, Partner in the crossover team at Sofinnova Partners, added: “The European healthcare market has matured with hundreds of late stage private and public companies looking for growth capital, and Sofinnova Partners, with its name, track record and experience, is particularly well positioned to identify the best European deals and transform them into global leaders.”

Triago acted as placement agent and Clifford Chance Europe LLP acted as legal counsel on Sofinnova Crossover I.

* Bpifrance directly and with the “Investment for the Future” Program, managed by the SGPI and operated by Bpifrance

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead investor in start-ups and corporate spin-offs and has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management.

20/06/2000
17/05/2000
08/05/2000
29/03/2000
23/03/2000
15/02/2000
14/02/2000
27/01/2000
04/11/1999

Hayward CA. -Kosan Biosciences, Inc. announced today that Susan M. Kanaya has joined the company as Vice President, Finance and Chief Financial Officer.


“Susan brings more than fifteen years of experience in financial planning and management to Kosan,” said Michael S. Ostrach, Chief Operating Officer. “Her expertise will be extremely valuable as Kosan continues its development from a development stage company into an operating company.”


Prior to joining Kosan, Ms. Kanaya was Vice President, Finance at SUGEN, Inc., a publicly-held biotechnology company that recently became a subsidiary of Pharmacia & Upjohn. Since joining SUGEN in 1994 Ms. Kanaya held various positions in Finance and was responsible for financial planning and analysis, financial reporting, corporate financings and treasury and risk management.


Before joining SUGEN, Ms. Kanaya was the Controller at 50/50 Micro Electronics, Inc. and at Power Up Software Corporation. She also held financial analyst and accounting positions at American President Lines, Ltd., Wells Fargo Bank and KPMG Peat Marwick.


Ms. Kanaya graduated from the University of California, Berkeley with a BS in Business Administration, with an emphasis on Accounting and Finance.


Kosan Biosciences, Inc. is a privately held biotechnology company focused on generating small molecule compounds by genetic engineering of biosynthetic pathways, with an initial focus on polyketides. Kosan’s technology permits modifications of polyketides not feasible by chemical methods, greatly expanding the repertoire of polyketides. Therapeutic targets for the Company’s compounds include infectious diseases, gastrointestinal motility disorders, respiratory inflammation, cancer, nerve regeneration and immunosuppression.


For further information :


Daniel V. Santi, M.D., Ph.D. CEO and President KOSAN Biosciences, Inc. 3832 Bay Center Pl. Hayward, CA 94545 www.kosan.com Tel: 510-732-8400 ext. 204 Fax: 510-732-8401


Andrew Lloyd & Associates 95 Ditchling Road Brighton BN1 4ST +44-1273 675100 – Andrew Lloyd email : allo@ala.com


Visit website http://www.kosan.com

29/10/1999

Allschwil. Actelion Ltd. today announced that it has begun its international
Phase III clinical development program on tezosentan for intravenous use in
patients with acute heart failure.


Tezosentan is the first endothelin receptor antagonist optimized for the
treatment of acute pathological conditions. It has a rapid onset of action and a
short half-life allowing an easy titration. The results of the US Phase II
clinical trials will be presented at the American Heart Association Meeting in
Atlanta early November.


“Our goal is to establish tezosentan as the major emergency drug for the
treatment of acute heart failure,” commented Martine Clozel, Vice-President at
Actelion and discoverer of tezosentan. “We believe that tezosentan may have
substantial benefits over existing therapy.”


Acute heart failure is a clinical entity resulting from an acute failure of
the cardiac pump to meet the needs of peripheral metabolism. It is the number
one cause of hospitalization in the elderly. In the US alone, more than 1.5
million patients are hospitalized per year for acute heart failure.


Located in Allschwil, Switzerland, Actelion Ltd. is an emerging
pharmaceutical company aiming to bring to the market innovative proprietary
drugs through creative science related to the endothelium. Founded in December
1997, Actelion Ltd. is backed by leading international venture capital and
private investment funds.

Contact person for Actelion: Dr. Peter
Herrmann, Vice President, Head of Drug Registration and Communication Phone: +41
61 487 45 39, E-mail peter.herrmann@actelion.com


Visit website http://www.actelion.com